Search research articles
Contact Us
Filters
Showing results (331-340 of 350) with videos related to
Page
of 35
Sort By:
The Lancet. Global Health
|
November 18, 2022
Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial
David S Lawrence, Charles Muthoga, David B Meya, et al.
The New England Journal of Medicine
|
March 30, 2022
Effect of Early Treatment with Ivermectin among Patients with Covid-19
Gilmar Reis, Eduardo A S M Silva, Daniela C M Silva, et al.
JAMA
|
November 17, 2023
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial
Thomas G Stewart, Paulina A Rebolledo, Ahmad Mourad, et al.
The New England Journal of Medicine
|
December 17, 2025
Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis
David B Meya, Fiona V Cresswell, Biyue Dai, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 27, 2024
Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial
Russell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
The Lancet. Infectious Diseases
|
September 29, 2024
Advancing the chemotherapy of tuberculous meningitis: a consensus view
Sean Wasserman, Joseph Donovan, Evelyne Kestelyn, et al.
JAMA Network Open
|
October 18, 2024
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial
Russell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
BMJ Open
|
April 4, 2019
AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study
Ponego Lloyd Ponatshego, David Stephen Lawrence, Nabila Youssouf, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 20, 2022
Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial
David R Boulware, Thomas A Murray, Jennifer L Proper, et al.
The Lancet. Infectious Diseases
|
June 11, 2023
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial
Carolyn T Bramante, John B Buse, David M Liebovitz, et al.
Page
of 35
Search research articles
Search
Showing results (331-340 of 350) with videos related to
Sort By:
Page
of 35
The Lancet. Global Health
|
November 18, 2022
Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial
David S Lawrence, Charles Muthoga, David B Meya, et al.
The New England Journal of Medicine
|
March 30, 2022
Effect of Early Treatment with Ivermectin among Patients with Covid-19
Gilmar Reis, Eduardo A S M Silva, Daniela C M Silva, et al.
JAMA
|
November 17, 2023
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial
Thomas G Stewart, Paulina A Rebolledo, Ahmad Mourad, et al.
The New England Journal of Medicine
|
December 17, 2025
Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis
David B Meya, Fiona V Cresswell, Biyue Dai, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 27, 2024
Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial
Russell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
The Lancet. Infectious Diseases
|
September 29, 2024
Advancing the chemotherapy of tuberculous meningitis: a consensus view
Sean Wasserman, Joseph Donovan, Evelyne Kestelyn, et al.
JAMA Network Open
|
October 18, 2024
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial
Russell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
BMJ Open
|
April 4, 2019
AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study
Ponego Lloyd Ponatshego, David Stephen Lawrence, Nabila Youssouf, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 20, 2022
Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial
David R Boulware, Thomas A Murray, Jennifer L Proper, et al.
The Lancet. Infectious Diseases
|
June 11, 2023
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial
Carolyn T Bramante, John B Buse, David M Liebovitz, et al.
Page
of 35